| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 7,612,052
- Publication Date: November 03, 2009
- Appl. No: 12/019294
- Application Filed: January 24, 2008
- Assignees: Novartis AG (Basel, CH)
- Claim: 1. A combination which comprises (a) a vasculostatic compound which is a VEGFR inhibitor and (b) an epothilone derivative of formula I [chemical expression included] wherein A represents O or NR N , wherein R N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
- Claim: 2. Combination according to claim 1 wherein the vasculostatic compound is PTK787.
- Claim: 3. Combination according to claim 1 comprising an epothilone derivative of formula I wherein A represents O, R is lower alkyl or hydrogen and Z is O or a bond.
- Claim: 4. Combination according to claim 1 , which is a combined preparation or a pharmaceutical composition.
- Claim: 5. Method of treating a warm-blooded animal having a solid tumor disease comprising administering to the animal a combination according to claim 1 in a quantity which is jointly therapeutically effective against a proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.
- Claim: 6. Method of treating according to claim 5 wherein PTK787 is employed and the solid tumor disease is ovarian cancer, lung cancer, head or neck cancer, cervix cancer, prostate cancer or colon cancer.
- Claim: 7. A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a solid tumor disease of a pharmaceutical combination according to claim 1 and at least one pharmaceutically acceptable carrier.
- Claim: 8. A commercial package comprising (a) a vasculostatic compound which is a VEGFR inhibitor and (b) an epothilone derivative of formula I [chemical expression included] wherein A represents O or NR N , wherein R N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, together with instructions for simultaneous, separate or sequential use thereof in the delay of progression or treatment of a solid tumor disease.
- Claim: 9. A combination of claim 2 wherein the epothilone derivative is epothilone B.
- Current U.S. Class: 514/102
- Patent References Cited: 2409754 October 1946 Henze ; 3475486 October 1969 Irani et al. ; 3962432 June 1976 Schmidt-Dunker ; 4746654 May 1988 Breliere et al. ; 4814326 March 1989 Rosini et al. ; 4927814 May 1990 Gall et al. ; 5405994 April 1995 Bonnery et al. ; 5583122 December 1996 Benedict et al. ; 5849726 December 1998 Brenner et al. ; 6302838 October 2001 O'Reilly et al. ; 2002/0061866 May 2002 Bataille et al. ; 2 775 187 August 1999 ; WO 94 14455 July 1994 ; WO 98 35958 August 1998 ; WO 99 01124 January 1999 ; WO 99 02514 January 1999 ; WO 99 39694 August 1999 ; WO 00 00485 January 2000 ; WO 00 18439 April 2000 ; WO 00 49019 August 2000 ; WO 00 59485 October 2000 ; WO 00 71104 November 2000 ; WO 01 49295 July 2001 ; WO 02 072085 September 2002
- Other References: Stearns M. E. et al., “Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice,” Invasion Metastasis, vol. 16(3), pp. 116-131 (1996). cited by other ; Diel I. J. et al., “Reduction in new metastases in breast cancer with adjuvant clodronate treatment,” New England Journal of Medicine, vol. 339(6), pp. 357-363 (1998). cited by other ; Wood J. M. et al. “PTK787/ZK 222584, A novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration,” Cancer Research, vol. 60(8), pp. 2178-2189 (2000). cited by other ; Schmidt P. et al., Tatsaechlicher Nutzen oder nur kein Schaden? Bisphosphonate in der Onkologie, Pharmacie in unserer Zeit, Nr. 6, pp. 519-527 (2001) (only available in German Language). cited by other ; Yano et al., “Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation,” Clinical Cancer Research, vol. 6(3), pp. 957-965 (2000). cited by other ; Seiden M. V. et al., “Ovarian cancer,” Oncologist, vol. 6(4), pp. 327-332 (2001). cited by other ; Gillis R.A. et al., “Depression of cardiac synpathetic nerve activity by diphenylhydantoin,” The Journal of Pharmacology and Experimental Therapeutics, vol. 179, pp. 599-610 (1971). cited by other ; Quimby O. T. et al., “Tetrasodium carbonyldiphosphonate, synthesis, reactions, and spectral properties,” J. Org. Chem., vol. 32, pp. 4111-4114 (1967). cited by other ; Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), Calabresi, et al, Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229. cited by other
- Primary Examiner: Henley, III, Raymond J
- Attorney, Agent or Firm: Dohmann, George R.
|
